Allogene Therapeutics (ALLO) Consolidated Net Income (2018 - 2026)
Allogene Therapeutics recorded quarterly Consolidated Net Income of -$42.8 million in Q1 2026, down 9.63% quarter-over-quarter from -$39.1 million in Q4 2025, and up 28.43% year-over-year from -$33.3 million in Q1 2025.
Allogene Therapeutics' Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$42.8 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 28.43% year-over-year to -$42.8 million; the TTM figure through Mar 2026 stood at -$174.1 million (up 30.08% YoY), while the FY2025 annual figure was -$190.9 million, up 25.9% from the prior year.
- Consolidated Net Income came in at -$42.8 million for Q1 2026 at Allogene Therapeutics, down from -$39.1 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$39.1 million in Q4 2025 to a low of -$97.0 million in Q1 2023.
- A 5-year average of -$66.3 million and a median of -$65.2 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income tumbled 5046.54% in 2022 and jumped 36.6% in 2025, its largest moves.
- Allogene Therapeutics' Consolidated Net Income stood at -$93.6 million in 2022, then rose by 15.8% to -$78.8 million in 2023, then gained by 27.02% to -$57.5 million in 2024, then soared by 32.13% to -$39.1 million in 2025, then declined by 9.63% to -$42.8 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$42.8 million, -$39.1 million, and -$41.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | -42.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.82 Mn |
| Dec 31, 2025 | -39.06 Mn |
| Sep 30, 2025 | -41.32 Mn |
| Jun 30, 2025 | -50.90 Mn |
| Mar 31, 2025 | -59.83 Mn |
| Dec 31, 2024 | -57.54 Mn |
| Sep 30, 2024 | -65.17 Mn |
| Jun 30, 2024 | -66.44 Mn |
| Mar 31, 2024 | -64.07 Mn |
| Dec 31, 2023 | -78.84 Mn |
| Sep 30, 2023 | -56.79 Mn |
| Jun 30, 2023 | -76.76 Mn |
| Mar 31, 2023 | -97.03 Mn |
| Dec 31, 2022 | -93.64 Mn |
| Sep 30, 2022 | -81.51 Mn |
| Jun 30, 2022 | -76.30 Mn |
| Mar 31, 2022 | -79.52 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | -77.28 Mn |
| Jun 30, 2021 | -70.41 Mn |
| Mar 31, 2021 | -33.20 Mn |
| Dec 31, 2020 | -68.57 Mn |
| Sep 30, 2020 | -66.20 Mn |
| Jun 30, 2020 | -60.97 Mn |
| Mar 31, 2020 | -54.48 Mn |
| Dec 31, 2019 | -61.03 Mn |
| Sep 30, 2019 | -50.74 Mn |
| Jun 30, 2019 | -41.20 Mn |
| Mar 31, 2019 | -31.59 Mn |
| Dec 31, 2018 | -30.51 Mn |
| Sep 30, 2018 | -43.50 Mn |
| Jun 30, 2018 | -134.90 Mn |
| Mar 31, 2018 | -2.60 Mn |